Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer

ABSTRCTDysregulated HGF/c-Met pathway has been implicated in multiple human cancers and has become an attractive target for cancer intervention. Herein, we report the discovery of -(3-fluoro-4-((2-(3-hydroxyazetidine-1-carboxamido)pyridin-4-yl)oxy)phenyl)-1-(4-fluorophenyl)-4-methyl-6-oxo-1,6-dihydr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2024-12, Vol.39 (1), p.2286435
Main Authors: Sima, Lijie, Wang, Zhongyuan, Yu, Ling, Hou, Youli, Zhao, Dongsheng, Luo, Bilan, Liao, Weike, Liu, Xinfu
Format: Article
Language:English
Subjects:
antitumor activity
c-Met
LAH-1
NSCLC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRCTDysregulated HGF/c-Met pathway has been implicated in multiple human cancers and has become an attractive target for cancer intervention. Herein, we report the discovery of -(3-fluoro-4-((2-(3-hydroxyazetidine-1-carboxamido)pyridin-4-yl)oxy)phenyl)-1-(4-fluorophenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide ( ), which demonstrated nanomolar MET kinase activity as well as desirable antiproliferative activity, especially against EBC-1 cells. Mechanism studies confirmed the effects of on modulation of HGF/c-Met pathway, induction of cell apoptosis, inhibition on colony formation as well as cell migration and invasion. In addition, also showed desirable ADME properties as well as acceptable PK parameters. The design, synthesis, and characterisation of are described herein.
ISSN:1475-6366
1475-6374
1475-6374
DOI:10.1080/14756366.2023.2286435